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When being interested in administering the best of two treatments to an individ-
ual patient i, it is necessary to know the individual treatment effects (ITEs) of the
considered subjects and the correlation between the possible responses (PRs) Y 1i and
Y 0i for two treatments 1 and 0. When data are generated in a parallel–group design
RCT, it is not possible to determine the ITE for a single subject since we only observe
two samples from the marginal distributions of these PRs and not the corresponding
joint distribution due to the ’Fundamental Problem of Causal Inference’ [Holland,
1986, p. 947]. In this article, we present a counterfactual approach for estimating
the joint distribution of two normally distributed responses to two treatments. This
joint distribution of the PRs Y 1i and Y 0i can be estimated by assuming a normal joint
distribution for the PRs and by using a normally distributed baseline biomarker Zi
which is defined to be functionally related to the sum Y 1i + Y 0i . Such a functional
relationship is plausible since a biomarker Zi and the sum Y 1i + Y 0i encode for the
same information in a RCT, namely the variation between subjects. As a result of
the interpretation of the biomarker Zi as a proxy for the sum Y 1i + Y 0i , the esti-
mation of the joint distribution is subjected to some constraints. These constraints
can be framed in the context of linear regressions with regard to the proportions of
variances in the responses explained and with regard to the residual variation. As a
consequence, a new light is thrown on the presence of treatment–biomarker interac-
tions. We applied our approach to a classical medical data example on exercise and
heart rate.
1 Introduction
Let us start with a randomized controlled trial (RCT) where two treatments denoted by
1 (for example new treatment) and 0 (for example placebo) are compared. Let Y ji with
j ∈ {0,1} be the potential response (PR) to the treatment when subject i is assigned to
treatment j. However, we cannot simultaneously observe both responses Y 1i and Y 0i due to
the ’Fundamental Problem of Causal Inference’ [Holland, 1986, p. 947]. Thus, the observed
response Yi is given by
Yi = Y 1i Ti+Y 0i (1−Ti) (1. 1)
where Ti ∈ {0,1} denotes the treatment allocated to subject i. Nonetheless, it is of interest
to know the joint distribution of the PRs since we then could determine the ’Individual
Treatment Effect’ (ITE) Y 1i −Y 0i and thus we would know the probability a subject would
benefit from either of both compared treatments. Such knowledge allows a physician
to apply the best treatment for a subject. Due to the ’Fundamental Problem of Causal
Inference’ [Holland, 1986, p. 947], the expected difference of the PRs can only be estimated
where this difference
E[Y 1i −Y 0i ] = E[Y 1i ]−E[Y 0i ] (1. 2)
is commonly known as ’Average Treatment Effect’ (ATE) and can be estimated from the
observed marginals of the PRs. If the difference Y 1i −Y 0i and thus the ITE is constant
for every subject i then no subject–treatment additivity is present. If not, an interaction
between the treatments and the subjects (subject–treatment interaction) is present.
2
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In a RCT, it is possible to approximate the joint distribution of the PRs by using a repli-
cated crossover design. This design is usually used for evaluating individual bioequivalence
which allows separate estimates of between–subject variation, subject–treatment interac-
tions (in this context called ’subject–formulation interaction’) and within–subject variation
[Senn, 2001]. Besides, unreplicated crossover trials are used to determine the correlation
between the responses of two compared treatments: a positive correlation results when
treatments with similar ’modes of action’ are compared whereas a negative correlation re-
sults when treatments with different ’modes of actions’ are compared [Cleophas, 1996a,b;
Cleophas and de Vogel, 1998; Cleophas, 2000].
In situations where a crossover design is not feasible (for example eradication therapies in
infectious diseases and cancer), we can only use a parallel–group RCT. When using such
a design, subject effects (between–subject variation) can be approximated by biomarkers
(known as ’prognostic biomarkers’) and subject–treatment interactions can be approxi-
mated by treatment–biomarker interactions (known as ’predictive biomarkers’) as insinu-
ated by Senn [2001]. In drug development, often a biomarker is used for guiding treatment
options. Such a biomarker is commonly labeled ’companion diagnostic (cDx)’. The most
prominent example is the biomarker Her-2/neu used in breast cancer for making a decision
of treating patients with trastuzumab.
Assume a trivariate normal distribution for the two PRs and the biomarker Zi. The








where µ1 is the mean of Y 1i , µ0 is the mean of Y 0i and µZ is the mean of Zi and variance–








where σ2j is the variance of Y
j
i and σ2Z is the variance of Zi. The correlation between Y 1i
and Y 0i is denoted by ρ10, the correlation between Y
j
i and Zi by ρj . In short, the PRs
and the biomarker are distributed as (Y 1i ,Y 0i ,Zi)′ ∼ N [µM ,ΣM ]. The trivariate normal
distribution implies that the ATE is given by
∆ = µ1−µ0. (1. 3)
Further, the trivariate normal distribution implies that the joint distribution of Y ji and Zi
is bivariate normal. Following, for example, Johnson and Wichern [1992, p. 128, 138–139],
the conditional distribution of Y ji given Zi is











αj = µj−βjµZ , (1. 5)
σ2j|Z = σ2j (1−ρ2j) (1. 6)
hold. Since we cannot observe both PRs in a parallel–group RCT we can only estimate
the quantities αj , βj and σ2j|Z for both treatment groups. Thus, we can calculate the
expected value of the response Y ji conditional on the biomarker Zi, E[Y
j
i | Zi], by a linear
relationship described by the intercept αj and the slope βj . Based on the linear relationship,
the expected difference E[Y 1i −Y 0i | Zi], can be estimated. If the difference E[Y 1i −Y 0i | Zi]
is constant for every value of the biomarker Zi then treatment–biomarker additivity will be
present. If not, an interaction between the treatments and the biomarker is present. Such
an interaction is commonly modeled in a parallel–group RCT by including an interaction
term between treatment and biomarker in a linear regression model.
However, such an interaction term and the resulting difference E[Y 1i −Y 0i | Zi] tells us only
the half of the truth. The regression term only allows the estimation of the mean of the
distribution of the ITEs Y 1i −Y 0i (unconditional or conditional on Zi) but it does not allow
the estimation of the variance of the ITEs since this variance depends on the correlation
between the PRs. In the case of the unconditional ITEs Y 1i −Y 0i , the variance is given by
σ2∆ = σ21 +σ20−2ρ10σ1σ0 (1. 7)
where ρ10 is the sole unobservable quantity of σ2∆. If no treatment–biomarker interac-
tions or no subject–treatment interactions are present, the corresponding variances of the
conditional and unconditional ITEs are zero.
In order to determine the variance of the ITE the dependence structure of the two PRs
has to be known. As a consequence, it is necessary to make some assumptions about
the joint distribution of the two PRs where the the dependence between the two PRs is
described by a dependence measure like a correlation coefficient. In the case of normally
distributed PRs, Gadbury and Iyer [2000] and Gadbury et al. [2001] rely on the trivariate
normal distribution and derive bounds for the correlation coefficient ρ10 of the variance–
covariance matrix ΣM . The correlation coefficient ρ10 can be bounded due to the fact that
the matrix ΣM of the trivariate normal distribution has to be positive definite. Knowing
the correlation coefficient ρ10 allows in consequence the bounding of the variance of the
ITEs (unconditional or conditional on Zi) as outlined by Gadbury and Iyer [2000] and
Gadbury et al. [2001].
The following article studies the trivariate normal distribution as a model to evaluate the
variation of ITEs when the PRs Y 1i and Y 0i and the biomarker Zi are generated in a
parallel–group RCT. But unlike Gadbury and Iyer [2000] and Gadbury et al. [2001], we
define a functional relationship between the baseline biomarker Zi and the PRs. As a
consequence, a point estimator for the correlation coefficient ρ10 is obtainable instead of
an estimate for the lower and the upper bound which usually cover a wide range of ρ10 and
are thus less of practical value as already noticed by Lord [1955]. With a point estimate
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of the correlation between the PRs, their joint distribution can be estimated and a point
estimator for the variation of the ITEs can be derived. This allows the assessment of
whether or not subject–treatment interactions are present. Additionally, it should also be
noted that knowledge about the correlation parameter ρ10 can be used for planning RCTs
with less subjects if this correlation is positive enabling a more rapid and economic drug
development.
The article is organized as follows. In Section 2, the model for estimating the joint distri-
bution of the PRs is presented. We assume normal marginal distributions of the responses
under treatment 1 and 0, respectively. Further, assumptions on the biomarker for estimat-
ing the joint distribution are presented. In Section 3, estimators for estimating the joint
distribution and corresponding variances are derived within the framework of the maxi-
mum likelihood theory. Conditions for the existence of variation in ITEs are presented.
In Chapter 4, a medical data example is presented which is analyzed by the developed
methodology for estimating joint distributions. In Chapter 5, the limitations of the pre-
sented methodology are discussed and an outlook for further issues of research is given.
2 A model for estimating the joint distribution
A model for estimating the joint distribution of the PRs is presented. Before starting,
assumptions about the PRs with regard to the mechanism of how the data are generated
are made. These assumptions lean on Cheng et al. [2009, p. 21]. Assume, firstly, that the
PR of subject i is independent of the allocation of the treatments to the subjects other
than subject i commonly known as ’Stable Unit Treatment Value Assumption (SUTVA)’,
secondly, that a subject enrolled in the RCT is an independent and identically distributed
random sample from a well–defined population and thirdly, that there is independence
between the allocation Ti and Zi guaranteed by random allocation.
The following definition relates the biomarker Zi to the ITE such that the biomarker Zi
can be used to estimate the joint distribution of Y 1i and Y 0i .
Definition 2.1. The biomarker Zi is defined as variable given by
Zi = λ+κ(Y 1i +Y 0i ) +ηi (2. 8)
where λ and κ are constants and the error term ηi is assumed to be independent of Y ji ,
ηi ⊥ Y ji , independent of (Y 1i + Y 0i ), ηi ⊥ (Y 1i + Y 0i ) and independent of εji , ηi ⊥ εji , and
identically and independently distributed (iid) as ηi | Y 1i +Y 0i ∼N[0,σ2η] where σ2η denotes
the variance of ηi. The distribution of the variable Zi is as follows distributed.
Theorem 2.2. If the random variables (Y 1i ,Y 0i ,ηi)′ have a normal distribution then the
linear combination in Definition 2.1 will be normally distributed with mean value λ+κ(µ1 +
µ0) and variance κ2
(
σ21 +σ20 + 2ρ10σ1σ0
)
+σ2η.
Proof. The proof is standard and can be done by using characteristic functions for normally
distributed random variables (see, for example, Bryc [1995, pp. 12-13]).
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Remark 2.3. In the following it is elaborated why the biomarker Zi can be used as a
proxy of the sum Y 1i + Y 0i and not, for example, the difference Y 1i − Y 0i . The idea for
interpreting the variable Zi as a proxy of the sum Y 1i +Y 0i is best understood by a plot of
the PRs Y 0i against Y 1i where a line with intercept equal to zero and slope equal to one
(identity line) is added. This line indicates equality and perfect agreement between the
two treatments 1 and 0 in the case that the ATE for the compared treatments 1 and 0
is zero. Following Bartko [1994, p. 741], variation alongside this line quantifies variation
in the subject effects, that is ’between–subject variation’ [Shumaker and Metzler, 1998,
p. 1067], whereas variation orthogonal to this line quantifies variation in treatment effects
among subjects which all have the same subject effect, that is ’within–subject variation’
[Shumaker and Metzler, 1998, p. 1067]. Subject–treatment interactions are present when
the PRs do not cluster around the line indicating equality of treatments as shown in the
left plot of Figure 1.
Rotating the scatter plot graphing Y 0i against Y 1i by 45◦ in a clockwise manner yields a
plot known as ’Tukey sum–difference graph’ [Cleveland, 1985, p. 122]. This plot can be
produced by graphing the differences Y 1i −Y 0i against the sums Y 1i +Y 0i . The diagonal
line indicating equality of treatments shown in the non–rotated scatter plot is now a line
with an intercept of zero and a slope of zero. Now, variation along the x–axis and thus
in the sums Y 1i +Y 0i represents variation in subject effects. It is well known that subject
effects can be approximated by a baseline biomarker Zi in parallel–group design RCTs (see,
for example, Senn [2001]). Thus, it is reasonable to make the assumption of a functional
relationship between the sum Y 1i +Y 0i and the biomarker Zi since the sum Y 1i +Y 0i and the
biomarker Zi encode for the same information, namely the variation in the subject effects.
The corresponding sum–difference graph of the scatter plot of the left plot of Figure 1 is
shown in the right plot of Figure 1.
After having made the definition of the variable Zi, the trivariate normal distribution with
that variable is given as follows.
Theorem 2.4. The joint distribution of (Y 1i ,Y 0i ,Zi)′, where Zi is interpreted as variable

















where σ2Z = κ2(σ21 + σ20 + 2ρ10σ1σ0) + σ2η. This variance–covariance matrix ΣR is non–
negative definite for ρ10 ∈ [−1,1] and positive definite for ρ10 ∈ (−1,1).
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Zi = f(Yi1 + Yi0, ηi)






Figure 1: Left plot: Scatter plot of Y 0i on Y 1i with subject–treatment interactions showing
between– and within–subject variation and reference line of no subject–treatment interac-
tions (dashed grey line). Right plot: Corresponding sum–difference plot of the scatter
plot with the assumed functional relationship of the sum Y 1i +Y 0i and Zi.
Proof. The proof can be found in the Appendix.
Now, the trivariate normal distribution is completely described by the parameters θR =
(µ1,µ0,σ21,σ20,ρ10,κ,λ,σ2η)′. The information about the parameter ρ10, which is necessary
for estimating the joint distribution of Y 1i and Y 0i , is ’contained’ in the correlations between
Y ji and Zi. These correlations can be estimated in parallel–group RCTs.
3 Maximum likelihood estimation
In the following, we propose estimators of the parameters of the trivariate normal distribu-
tion with the variable Zi given in Definition 2.1. To this end, we represent data generated in
a parallel–group RCT by (Yi,Ti,Zi) considering two separated treatment groups. We start
with deriving maximum likelihood estimators of the parameters (µZ ,σ2Z ,αj ,βj ,σ2j|Z). They
will be used to derive the estimates needed for estimating the joint distribution of the PRs
Y 1i and Y 0i and the variable Zi as specified by the parameters (µ1,µ0,σ21,σ20,ρ10,κ,λ,σ2η)′.
Further, conditions where the estimation of the joint distribution of the PRs is possible are
shown. For each subject i either response Y 1i or Y 0i is observable. This results in a missing
value problem with respect to the PRs Y 1i or Y 0i per subject. This was first recognized by
Lord [1955] and Anderson [1957]. Their ideas are summarized in the following proposition.
Theorem 3.1. Assume Y 1i and Zi are iid as bivariate normal distribution with means µ1
and µZ , variances σ21 and σ2Z and the correlation coefficient ρ1. The corresponding real-
izations are denoted by y1i and zi and the corresponding normal densities by φ[zi;µZ ,σ2Z ]×
7
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φ[y1i ;α1 +β1zi,σ21|Z ]. By analogy, assume Y 0i and Zi are iid as bivariate normal distribu-
tion with means µ0 and µZ , variances σ20 and σ2Z and the correlation coefficient ρ0. The
corresponding realizations are denoted by y0i and zi and the corresponding normal densities
by φ[zi;µZ ,σ2Z ]×φ[y0i ;α0 +β0zi,σ20|Z ].
Let N be the sample size and let the treatment indicator Ti be independently distributed
from Zi, Ti ⊥ Zi, where the proportion ψ of N is allocated to treatment 1 and 1−ψ of
N is allocated to treatment 0. Hence, ψN = n1 observations (y1i , z1i )′ and (1−ψ)N = n0
observations (y0i , z0i )′ are given where the data are sorted by the treatment indicator leading
to the following data structure (adapted from Anderson [1957, p. 202])
z1, . . . , zn1 , zn1+1, . . . , zn1+n0
y11, . . . ,y
1
n1 ,
y0n1+1, . . . ,y
0
n1+n0
with i ∈ {1, . . . ,n1,n1 + 1, . . . ,n1 +n0}.
The sample space X of (Y 1i ,Zi)′ and (Y 0i ,Zi)′ is (R2)n1 ∪ (R2)n0. Further, the parameter
space is
ΘC ≡ {(µZ ,σ2Z ,α1,α0,β1,β0,σ21|Z ,σ20|Z)(µZ ,α1,α0,β1,β0) ∈R5,(σZ ,σ1|Z ,σ0|Z) ∈R3+}.









i − µ̂2Z . (3. 10)














i − ȳj)2− β̂2j 1nj
∑nj
i=1(zi− z̄j)2 (3. 13)




i and z̄j = 1nj
∑nj
i=1 zi.
Proof. The proof can be found in the Appendix.
Before proceeding to the estimation of the parameters θR = (µj ,σ2j ,ρ10,κ,λ,σ2η)′, we provide
marginal parameters θM = (µj ,µZ ,σ2j ,σ2Z ,ρj)′ for they are useful in the estimation of the
parameters θR.
Theorem 3.2.
µj = αj +βjµZ , (3. 14)










3 MAXIMUM LIKELIHOOD ESTIMATION
Substituting the parameters of θM by the corresponding estimators for θC provided in (3.
9)–(3. 13) gives the maximum likelihood estimators for θM denoted by
θ̂M = (µ̂j , µ̂Z , σ̂2j , σ̂2Z , ρ̂j)′.
The parameters θC are transformed by the function fM : ΘC→ΘM defined on the parameter
space
ΘM ≡ {(µ1,µ0,µZ ,σ1,σ0,σZ ,ρ1,ρ0) | (µ1,µ0,µZ) ∈R3,
(σ1,σ0,σZ) ∈R3+,(ρ1,ρ0) ∈ (−1,1)2}.
Proof. The proof can be found in the Appendix.
For estimation of the joint distribution of the PRs, the parameters θR = (µj ,σ2j ,ρ10,κ,λ,σ2η)′
have to be estimated.
Theorem 3.3. The parameters for µj and σ2j are already given in (3. 14)–(3. 15). The



































Substituting the parameters θR by the estimators for θC provided in (3. 9)–(3. 13) gives
the estimators for θR denoted by
(µ̂j , σ̂2j , ρ̂10, κ̂, λ̂, σ̂2η)′.
The vector θR is a bijective and continuous function of θC denoted by fCR : Θ?C→ΘR which














































(µ1,µ0,σ1,σ0,ρ10,κ,λ,ση) | (µ1,µ0,λ) ∈R3,
κ ∈R\{0},(σ1,σ0) ∈R2+\{σ0−σ1 = 0},





When transforming the marginal parameters θM to the parameters θR by the function
fMR : Θ?M →ΘR the parameter space Θ?M is defined as follows:
Θ?M ≡ΘM ∩
{{




{ρ20−ρ21 < 0}∩{σ20(1−ρ20)−σ21(1−ρ21)< 0}
}}
.
The asymptotic variances (and covariances) of θR can be derived by using the multivariate
delta method [Greene, 2003, Chapter D.2.7] and can be found in the Appendix.




































for the parameter space ΘC and the constraints
κ 6= 0 and σ20−σ21 6= 0
for the parameter space ΘR are necessary so that the function fCR is bijective and no
discontinuity in the function fCR occurs and thus the estimation of the joint distribution of
the PRs Y 1i and Y 0i becomes possible. As a consequence, the maximum likelihood estimate
of the parameters θR has not to exist for some data (Yi,Zi,Ti).
As explained in Remark 3.4 the estimates of parameters θR only exist if both the difference
ρ̂20− ρ̂21 and the difference σ̂20|Z − σ̂21|Z have each the same sign. Conversely, the estimates
of parameters θR do not exist if these differences are of opposite signs.
4 Data example
A classical example of a RCT is taken from Schwenke [1990, Table 1]. The RCT randomized
24 patients to three types of exercise programs in a randomization ratio of 1 : 1 : 1 (8
patients per exercise program). The clinically relevant endpoint is the heart rate observed
after treatment where a lower value is more favorable. The biomarker Zi is the baseline
heart rate [Schwenke, 1990, p. 444]. Similar to Schwenke [1990, Figure 1], the scatter plot
in Figure 2 shows the data superimposed with the linear relationships between the heart
rate observed after treatment and the baseline heart rate separately for each exercise group.
Following Schwenke [1990, Table 3, ’Without Bonferroni Adjustment’], the contrast exercise
1 compared to exercise 3 (contrast A) and exercise 2 compared to exercise 3 (contrast B)
are considered so that in the following exercise 3 is regarded as reference treatment (Ti = 0).
10
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Figure 2: Plot of the heart rate observed after treatment yji under exercise 1, 2, and 3
vs. baseline heart rate z1i with estimated linear relationships.
Table 1: Estimates of selected parameters with corresponding asymptotic 95%
confidence intervals (CIs). The lower and upper limits of the confidence inter-
vals for some estimates are outside their range which is due to the fact that
asymptotic estimators instead of exact estimators are used.
Exercise 1 vs. 3 (N = 16) Exercise 2 vs. 3 (N = 16)
Estimate 95% CI Estimate 95% CI
Estimates of the restriction parameters:
ρ̂1 0.93 0.84, 1.01 0.94 0.86, 1.01
ρ̂0 0.64 0.25, 1.03 0.63 0.23, 1.03
σ̂1|Z 6.29 0.89, 8.85 3.58 0.51, 5.04
σ̂0|Z 3.32 0.47, 4.67 3.32 0.47, 4.67
Estimates of the parameters θR:
µ̂1 150.13 141.33, 158.93 163.26 157.98, 168.54
µ̂0 155.88 153.21, 158.55 156.06 153.42, 158.71
σ̂1 16.82 7.93, 22.43 10.15 4.87, 13.51
σ̂0 4.32 1.08, 6.02 4.26 1.03, 5.94
ρ̂10 0.53 -0.03, 1.08 0.35 -0.32, 1.02
κ̂ 0.51 0.37, 0.65 0.81 0.54, 1.09
λ̂ -86.29 -129.57, -43.02 -189.61 -276.69, -102.54
σ̂2η 11.93 -4.31, 28.17 2.19 -17.45, 21.82
Estimates of presentation parameters:
∆̂ -5.75 -13.74, 2.24 7.20 2.44, 11.96





0.35 0.14, 0.56 0.77 0.60, 0.95
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The crossing of the both lines of exercise 1 and 3 indicates a qualitative interaction for
contrast A whereas the nearly non–crossing lines of exercise 2 and 3 pronounces a quan-
titative interaction for contrast B. As a first step, it is checked of whether the restrictions
on the parameter space Θ?C are fulfilled so that the joint distribution of Y 1i and Y 0i can be
estimated. It can be seen from Table 1 that for both contrasts A and B ρ̂20− ρ̂21 < 0 and
σ̂20|Z− σ̂21|Z < 0 hold. Thus the estimates of the parameters θR will be in the corresponding
parameter space ΘR as explained by Remark 3.4.
Next, the estimates of the parameters θR with asymptotic 95% confidence intervals are
shown in Table 1. Exercise 1 is on average lower than exercise 3 with an ATE ∆̂ =−5.75
where the corresponding 95% confidence interval includes 0. In contrast, exercise 2 is on
average higher than exercise 3 with ∆̂ = 7.20 where the corresponding 95% confidence
interval does not include 0. However, the ATE is not informative about whether or not
there are patients which will more likely profit from exercise 1 (or 2) or more likely from
exercise 3. In order to get this information, it is necessary to know the correlation ρ10 for
the contrasts A and B. The correlations ρ̂10 are positive for both contrasts. The resulting
variation in ITEs is described by σ̂∆ and we can see that the corresponding 95% confidence
intervals do not include 0 for both contrasts indicating the presence of subject–treatment
interactions.
Based on the estimates of the parameters θR, the bivariate normal density of the estimated
joint distribution of the PRs Y 1i and Y 0i is drawn for both contrasts in Figure 3 (top row).
From this estimated joint distribution of Y 1i and Y 0i we can quantify the subgroup of
patients which will more likely benefit from exercise 1 (or 2) compared to exercise 3 and
vice versa what can be seen from the location of the normal density around the identity
line: In the upper wedge is the proportion of patients who will benefit from exercise 1
(or 2) whereas in the lower wedge is the proportion of patients who will benefit from
exercise 3. This subgroup can be quantified by the probability that Y 1i > Y 0i hold, that
is the probability that a higher (unfavorable) response is observed under exercise 1 (or





the cumulative distribution function of the standard normal distribution. Note that this





0.35, that is on average 35 out of 100 randomly selected patients from a population will
reach a higher unfavorable response under exercise 1 than under exercise 3 and thus should
be treated by exercise 3. Vice versa, on average 65 out of 100 randomly selected patients





observed. A similar reasoning holds for contrast B. Although the ATE is in clear favor
for exercise 3 in this case, there are nonetheless 23 out of 100 randomly selected patients
which will be harmed by exercise 3.
For clinical decision–making, it is of interest to have not only estimates with Zi ’integrated




but also to have estimates conditional on Zi = zi. Such estimates
are shown in Figure 3 (bottom row) where the treatment effects conditional on Zi are
shown with 95% confidence and prediction intervals and where probabilites that Y 1i > Y 0i
conditional on Zi holds are shown with asymptotic 95% confidence intervals. Details
on these estimators can be found in Laubender [2014]. For contrast A, it can be seen
that there is a clear distinction between those patients benefitting from exercise 1 or from
12
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Exercise 1 vs. exercise 3
























































































Exercise 2 vs. exercise 3




















































































Figure 3: The left column of plots refers to contrast A whereas the right column of plots
refers to contrast B. Top row: estimated joint distribution of heart rate after treatment
Y 1i and Y 0i where the corresponding values of µ1 and µ0 are added by vertical and horizon-
tal dotted lines. Further, the line of no difference between the two treatments is indicated
by the diagonal; Middle row: plot of the ITEs conditional on the baseline heart rate
Zi (solid line) with 95% confidence intervals (dashed lines) and 95% prediction intervals
(dotted lines) and with reference line (dashed–dotted line) of no treatment difference be-
tween exercises 1 and 3 and exercises 2 and 3; Bottom row: corresponding conditional
response probabilities P [Y 1i > Y 0i |Zi] (solid line) with reference line (dashed–dotted line)
of no treatment effect between exercises 1 and 3 and exercises 2 and 3.
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exercise 3 illustrating the qualitative nature of the treatment–covariate interaction whereas
for contrast B exercise 3 should be recommended for patients with higher values of the
baseline heart rate. Also note that the width of prediction interval as essential tool for
clinical decision–making depends on the correlation coefficient ρ10.
5 Discussion
5.1 Conclusions
When being interested in administering the best of two treatments to an individual patient,
it is necessary to know the ITEs of the considered subjects and the correlation between
the PRs Y 1i and Y 0i . When data are generated in a parallel–group design RCT, it is not
possible to determine the ITE for a single subject since we only observe two samples from
the marginal distributions of these PRs and not the corresponding joint distribution due
to the ’Fundamental Problem of Causal Inference’ [Holland, 1986, p. 947].
In this article, we present a counterfactual approach for estimating the joint distribution of
two normally distributed responses to two treatments. This joint distribution of the PRs Y 1i
and Y 0i can be estimated by assuming a normal joint distribution for the PRs and by using
a normally distributed baseline biomarker Zi which is defined to be functionally related to
the sum Y 1i +Y 0i . Such a functional relationship is plausible since a biomarker Zi and the
sum Y 1i +Y 0i encode for the same information in a RCT, namely the variation between
subjects. Further, monotone relationships are easily transformed into linear relationships.
As a result of the interpretation of the biomarker Zi as a proxy for the sum Y 1i +Y 0i , the
estimation of the joint distribution is subjected to some constraints. These constraints
should be framed in the context of linear regressions. Without loss of generality, the
constraints ρ̂20− ρ̂21 < 0 and σ̂20|Z− σ̂21|Z < 0 have to be fulfilled so that maximum likelihood
estimators for the parameters θR exist. In the context of linear regression, the quantity ρ2j
can be interpreted as proportion of the variance of Y ji explained by the biomarker Zi and
the quantity σ2j|Z can be regarded as unexplained or residual variance.
In order to understand the constraints ρ̂20− ρ̂21 < 0 and σ̂20|Z− σ̂21|Z < 0, assume without loss
of generality that we want to develop a cDx Zi for a new treatment 1, that a high response
is more favorable and that the variance σ21 is higher than the variance σ20 indicating the
presence of subject–treatment interactions (see, for example, Cox and Reid [2000, p. 21]).
In this case, it is essential to see how the comparison treatment 0 performs under that cDx
Zi so that a treatment–covariate interaction can be established. However, as outlined in
the Introduction, it is not sufficient to look only to the mean of the ITEs but also to the
variance of the ITEs (either unconditional or conditional on Zi). When looking at the ITEs
conditional on Zi, three types of (qualitative) interactions can be distinguished and are
exemplary shown in Figure 4. The scatter plots in Figure 4 show simulated responses of
treatment 1 (gray crosses) and 0 (black circles) stratified by the cDx Zi with corresponding
regression lines superimposed. The first interaction is shown in the top of Figure 4 and is
in accordance with the constraints ρ20−ρ21 < 0 and σ20|Z−σ21|Z < 0. For a high value of Zi,
we see that the conditional mean of treatment 1 is higher than that of treatment 0 and
14
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that higher responses under treatment 1 than under treatment 0 can be reached.
The second interaction is shown in the middle of Figure 4. In this case ρ20− ρ21 > 0 and
σ20|Z−σ21|Z < 0 hold so that the constraints are not fulfilled. For a high value of Zi, we can
now see that the conditional mean of treatment 0 is higher than under treatment 1 but
that under treatment 1 quite a lot higher responses can be reached under treatment 1 than
under treatment 0. Thus, the cDx Zi does not capture the variation of the responses Y 1i
as accurate as the variation of the responses Y 0i . In this case the strict focusing on mean
effects is misleading.
The third interaction is shown in the bottom of Figure 4. In this case ρ20− ρ21 < 0 and
σ20|Z −σ21|Z > 0 hold so that the constraints are not fulfilled. For very high values of Zi,
we see that the conditional mean of treatment 1 is higher than under treatment 0 and
that higher responses under treatment 1 can be reached than under treatment 0. However,
the lower the value of the cDx Zi becomes, a higher value of response under treatment 0
can be reached although the mean of Y 1i conditional on Zi is higher than the mean of Y 0i
conditional on Zi.
Besides, these constraints imply the following well–known situations of linear regression
modeling where no estimation of the parameters θR and thus the joint distribution of the
PRs Y 1i and Y 0i is possible: First, if ρ21 = ρ20 = 0 hold, then an uninformative biomarker Zi is
present. Nonetheless, there might be subject–treatment interactions present which cannot
be modeled by the uninformative biomarker Zi. Second, if ρ1 = ρ0 6= 0 and simultaneously
σ21|Z = σ20|Z hold then subject–treatment additivity is usually assumed in this situation.
Third, if ρ1 =−ρ0 or ρ0 =−ρ1 and simultaneously σ21|Z = σ20|Z hold then subject–treatment
interactions are present where, however, no subject effects are simultaneously present. This
fact is also in good accordance with the statement that subject–treatment interactions
’cannot be estimated separately from variation among the units’ [Cox and Reid, 2000,
p. 20]. From the point of view of the linear regression model an interaction without main
effect for the biomarker Zi is present.
Our model can be considered as a further development of the idea proposed by Gadbury
and Iyer [2000] which bounds the correlation ρ10 using a biomarker due to the requirement
of positive definitness of the variance–covariance matrix in a trivariate normal distribution.
In contrast, our approach provides a point estimate of ρ10 (with a corresponding confidence
interval).
Finally, our proposed approach facilitates a more–informed assessment of a biomarker’s
relevance for treatment selection than does the classical approach of testing for an inter-
action between marker and treatment in an ordinary regression model. As Huang et al.
[2012] have demonstrated, a strong interaction coefficient is important for a biomarker to
have value for treatment selection but is not useful for summarizing performance because it
depends on other coefficients in the risk model as well as the functional form of the model.
Therefore the interaction coefficient is not directly comparable between biomarkers (and
models).
To present the dependency between biomarker value and ITE we use plots of the response
function f [zi] = Pr[∆> 0|Zi = zi]. This provides useful information to individual patients
who have biomarker results in hand about their expected benefit of treatment given their
biomarker measure.
15










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4: Scatter plots of simulated responses Y ji and a biomarker Zi for treatment 1
(gray crosses) and for treatment 0 (black circles) with regression lines superimposed. All
three plots show a qualitative interaction. Only the top plot shows data which fulfill the
constraints ρ20−ρ21 < 0 and σ20|Z −σ21|Z < 0.
16
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Huang et al. [2012] propose the use of a ROC curve to characterize and compare biomark-
ers with respect to their treatment–selection capacity. Following their idea, we can de-
fine (assuming that high biomarker values favor treatment 1) the true positive fraction
TPF[zi] = Pr[Zi > zi|∆ > 0] and the false positive fraction FPF[zi] = Pr[Zi > zi|∆ < 0].
The ROC curve is given by ROC[t] = TPF[FPF−1[t]]. The TPF (as well as the FPF)
can be calculated from the function f [·] and the distribution of the biomarker Zi. As in
the work of Huang et al. [2012], our measures provide an overview of treatment–selection
capacity allowing the ITE threshold to vary. This is helpful in situations where there does
not exist a well–established decision threshold and the choice relies on other factors such
as the cost and side–effects of the active treatment.
Most of the methodological literature on treatment–selection markers assumes that the
statistical interaction between marker value and treatment assignment in the context of
a randomized trial is the primary measure of marker performance (as explained by some
references of Huang et al. [2012], in particular Sargent et al. [2005], Freidlin and Simon
[2005], Buyse et al. [2007], Simon [2008] and Simon et al. [2009]). However, a strong
interaction is important but not sufficient for adequate marker performance [Janes, 2011].
Specifically, two markers can have the same interaction but very different performance.
Huang et al. [2012] present an example where two biomarkers have the same interaction
coefficient but different capacity in terms of classifying a subject according to treatment
effectiveness. Therefore, we see the response function as a major information which has to
be communicated to clinicians (see Figure 3).
5.2 Limitations and issues for future research
The main limitation of our approach consists in its distributional assumptions. Since
simultaneous observations of both PRs Y 1i and Y 0i for a subject i are not possible it is a
challenge to assess the distributional assumptions, especially that the joint distribution of
the PRs follows a bivariate normal distribution. We consider copula models as alternative
to the bivariate normal distribution of the PRs. They allow normal marginal distributions
of the biomarker Zi and the PRs Y 1i and Y 0i and they allow bivariate distributions of Y 1i
and Zi and of Y 0i and Zi to be normal. Conditional copula models can be used to work out
such distributions [Veraverbeke et al., 2011]. It is important to stress that these observable
and assessable relationships—even made normally distributed by a transformation—do not
necessarily imply that the PRs follow a joint normal distribution.
A similar critical aspect consists in the distributional assumptions of the variable Zi created
by its linear relationship with the sum Y 1i +Y 0i . Here, it is an issue of research to explore
the potential of proper scoring rules (see for example Gneiting and Raftery [2007]) to assess
the correct functional relationship between biomarker Zi and the PRs Y 1i and Y 0i .
It is also of interest to study models where the correlation between the PRs Y 1i and Y 0i
may depend on a biomarker value. This aspect is not studied so far and is an issue for
future research. Finally, we would like to mention that the model is suited for univariate
biomarkers. It is an issue for future research to generalize to the use of multiple biomarkers
simultaneously. It is also of interest to apply the basic idea of this paper to other common
clinical outcomes like binary endpoints and survival times, especially to remove restrictions
17
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as introduced by Huang et al. [2012] to make the counterfactual model identifiable.
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B Appendix
B.1 Proof of Theorem 2
Proof. The mean vector (9) follows from µM and Theorem 1. The variances and covariances
between the responses Y 1i and Y 0i shown in the variance–covariance matrix ΣR follow from
ΣM . The variance of the variable Zi shown in the variance–covariance matrix ΣR follows
from Proposition 1. The covariance between the response Y 1i and the variable Zi is given
as follows.
Cov[Y 1i ,Zi] = Cov[Y 1i ,λ+κ(Y 1i +Y 0i ) +ηi]
= Cov[Y 1i ,κY 1i +κY 0i ]
= Cov[Y 1i ,κY 1i ] +Cov[Y 1i ,κY 0i ]
= κ
(
Cov[Y 1i ,Y 1i ] +Cov[Y 1i ,Y 0i ]
)
= κσ1(σ1 +ρ10σ0).
Note that the covariance between the response Y 1i and the error term ηi is assumed to be
zero, Cov[Y 1i ,ηi] = 0 as shown in Definition 1. The covariance between the response Y 0i
and the variable Zi can be derived by analogous line of reasoning to the derivation of the
covariance between response Y 1i and the variable Zi.
A matrix will be non–negative definite if the principal minors of this matrix are non–
negative [Searle, 1982, pp. 205–208]. It can be seen that the principal minors of the










The determinant of the variance–covariance matrix ΣR is thus given by σ21σ20σ2η(1− ρ210).
If the determinant of a matrix is not zero then the matrix is nonsingular and thus invert-
ible (see for example Searle [1982, p. 172]). It can be seen that the determinant of the
variance–covariance matrix ΣR is zero if |ρ10| = 1. However, the density of the trivariate
normal distribution requires that the variance–covariance matrix ΣR is invertible. Thus,
the variance–covariance matrix ΣR is invertible if ρ10 ∈ (−1,1).
18
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B.2 Proof of Theorem 3
Proof. Denote the conditional parameters θC = (µZ ,σ2Z ,α1,α0,β1,β0,σ21|Z ,σ20|Z)′. Consider










φ[y0i | zi]. (B. 23)
The likelihood function L[·] is splitted in three functions which have no parameters in com-
mon so that each function can be maximized independent of the other functions. Taking
the natural logarithm of each of the likelihood functions and maximizing these functions
for the parameters θC yields the estimators (9)–(13). It can be shown that these estimators
form a maximum. The corresponding asymptotic variances and covariances are derived by
relying on the expected information (for further details see Laubender [2014]).
B.3 Proof of Theorem 4
Proof. The parameters (µj ,σ2j ,ρj)′ are obtained by solving (4)–(6) for these parameters.
For the parameters (µZ ,σ2Z)′ the identity function is used. It can be immediately seen that
the parameters θM are a continuous and bijective function fM of the parameter space ΘC
to the parameter space ΘM . Since maximum likelihood estimators are invariant to bijective
transformations [Davidson and MacKinnon, 1993, pp. 253–255], the resulting estimators
of the marginal parameters θM are again maximum likelihood estimators.
B.4 Proof of Theorem 5
Proof. The estimators for (µj ,σ2j )′ are obtained by solving (4)–(6). To obtain estimators
for (ρ10,κ,λ,σ2η)′ in terms of the conditional parameters θC the following set of equations
19
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has to be solved for these parameters:
µZ = λ+κ(µ1 +µ0)
= λ+κ
(
(α1 +β1µZ) + (α0 +β0µZ)
)
, (B. 24)
σ2Z = κ2(σ21 +σ20 + 2ρ10σ1σ0) +σ2η
= κ2
(




































where the definitions of ρj , µZ and σ2Z follow from Proposition 2. Solving this set of
equations leads to estimators of (ρ10,κ,λ,σ2η)′ in terms of the conditional parameters θC .
The parameters θR are a continuous and bijective function fCR of the parameter space Θ?C
to the parameter space ΘR. Since maximum likelihood estimators are invariant to bijective
transformations [Davidson and MacKinnon, 1993, pp. 253–255], the resulting estimators
of the parameters θR are again maximum likelihood estimators.
To ensure that the estimators of the parameters θR are maximum likelihood estimators
with corresponding asymptotic properties, the invariance property of maximum likelihood
estimators [Davidson and MacKinnon, 1993, pp. 253–255] can be used. For that purpose,
the fact that the function fM : ΘC → ΘM is a continuous and bijective function of the
conditional parameters θC , is at first used. Thus, when relying on the invariance principle,
it has to be shown that the function fMR : Θ?M →ΘR is based both on a continuous function
and that an inverse of that function exists.
20
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Lemma B.1 (Continuity of the function fMR ). The function fMR is continuous if the
parameter space ΘM is restricted by either
ρ20−ρ21 > 0 and σ20(1−ρ20)−σ21(1−ρ21)> 0
or
ρ20−ρ21 < 0 and σ20(1−ρ20)−σ21(1−ρ21)< 0.
Proof. For the parameters (µ1,µ0,σ21,σ20)′ as functions of the parameters θM are identity
functions which are continuous functions. The parameter ρ10 is a rational function and thus
a continuous function (see for example Arens et al. [2012, pp. 194, 796]) provided that the
denominator does not reach a value of zero. Besides, the restriction of the parameter space
ΘR for ρ10 has to be fulfilled. To be specific, the absolute value of the denominator has to
be greater than the absolute value of the numerator. For the parameters (κ,λ)′ as rational
functions to be continuous, it has to be ensured that no division by zero occurs. Finally,
the parameter σ2η is a rational function and thus a continuous function provided that the
denominator does not reach a value of zero. Besides, the restriction of the parameter space
ΘR for σ2η has to be fulfilled. In particular, it has to be ensured that both the numerator
and the denominator are of the same signs. The restrictions on the parameter space ΘM
so that the function fMR [θM ] is continuous and fulfills the requirements of the parameter
space ΘR can be derived as follows where two cases have to be distinguished:
• Case 1: The signs of the numerator and denominator of σ2η are positive.
In this case, the following restrictions have to be considered.
I : |ρ0σ0−ρ1σ1|> |ρ1σ0−ρ0σ1|,
II : ρ0σ0−ρ1σ1 6= 0,
III : σ20(1−ρ20)−σ21(1−ρ21)> 0,
IV : σ20−σ21 > 0.
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The absolute values of inequality I are replaced by squaring. Rearranging the system
of inequalities leads to
I : (ρ20−ρ21)(σ20−σ21)> 0,
II : ρ0σ0−ρ1σ1 6= 0,
III : σ20(1−ρ20)> σ21(1−ρ21),
IV : σ20−σ21 > 0.
For inequality I to be true, the inequalities ρ20 > ρ21 and σ20 > σ21 follow. These in-
equalities imply that also inequality II and inequality IV are true. Besides, inequality
III imply the inequality σ20 > σ21 what can be shown as follows. Since the inequality
ρ20 > ρ
2
1 has to hold, ρ20 can be expressed as ρ21 + ξ where ξ = ρ20− ρ21. Thus, ξ is





1−ρ21− ξ︸ ︷︷ ︸
>1
. (B. 28)
For inequality (B. 28) to be true, it can be immediately seen that σ20 > σ21 has to
hold. As conclusion and summary, the system of inequalities lead to the restriction
of the parameter space ΘM shown in (23) by the inequalities ρ20−ρ21 > 0 and σ20(1−
ρ20)−σ21(1−ρ21)> 0 so that the function fMR is a continuous function.
• Case 2: The signs of the numerator and denominator of σ2η are negative.
In this case, the following restrictions have to be considered.
I : |ρ0σ0−ρ1σ1|> |ρ1σ0−ρ0σ1|,
II : ρ0σ0−ρ1σ1 6= 0,
III : σ20(1−ρ20)−σ21(1−ρ21)< 0,
IV : σ20−σ21 < 0.
By reasoning analogue to Case 1, it follows from this system of inequalities that
the inequalities ρ20− ρ21 < 0 and σ20(1− ρ20)− σ21(1− ρ21) < 0 have to be fulfilled for
restricting the parameter space ΘM shown in (23).
Lemma B.2 (Bijectivity of the function fMR ). The function fMR is bijective.
Proof. The parameters θR are obtained by solving fMR [θM ] for θM leading to the function
22
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gMR : ΘR→Θ?M . The values of gMR at θR are obtained by gMR [θR]:
µ1 = µ1, (B. 29)
µ0 = µ0, (B. 30)
µZ = λ+κ(µ1 +µ0), (B. 31)
σ21 = σ21, (B. 32)
σ20 = σ20, (B. 33)
σ2Z = κ2(σ21 +σ20 + 2ρ10σ1σ0) +σ2η, (B. 34)
ρ1 =
κ(σ1 +ρ10σ0)√




κ2(σ21 +σ20 + 2ρ10σ1σ0) +σ2η
. (B. 36)
The function fMR is only then an invertible function if the function fMR is bijective what
follows from the definition of an inverse function (see for example Arens et al. [2012, pp. 36,
187]). A function is bijective if it is both injective and surjective (see for example Arens
et al. [2012, pp. 36, 187]).
Injectivity is given, if gMR [fMR [θM ]] = θM for all θM ∈ Θ?M holds what is shown in the fol-
lowing:
µ1 = µ1 = µ1, (B. 37)
µ0 = µ0 = µ0,(B. 38)






= µZ , (B. 39)
σ21 = σ21 = σ21,(B. 40)
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Surjectivity is given, if fMR [gMR [θR]] = θR for all θR ∈ ΘR holds what is shown in the fol-
lowing:
µ1 = µ1 = µ1, (B. 45)
µ0 = µ0 = µ0, (B. 46)
σ21 = σ21 = σ21, (B. 47)

















= σ2η. (B. 52)
For injectivity and surjectivity to hold for the parameter spaces Θ?M and ΘR, the difference
σ20−σ21 is not allowed to be zero since a division by zero occurs in (B. 39), (B. 42)–(B. 44),
(B. 49)–(B. 52). For the same reason κ and ρ0σ0−ρ1σ1 are not allowed to be zero as can
be seen in (B. 49) and (B. 42)–(B. 44). Further, ρ20σ20− ρ21σ21 and σ20(1− ρ20)−σ21(1− ρ21)
are not allowed to simultaneously take a value of zero as shown by (B. 43) and (B. 44).
However, it can be seen that these restrictions are already considered by the restrictions
shown in Proposition B.1. Further, due to these restrictions the equation (B. 42) is positive.
Therefore, the function fMR is bijective and the inverse function is denoted by gMR is the
inverse of fMR . Thus, θ̂R = fMR [θ̂M ] is the maximum likelihood estimator of θR.
Lemma B.3. The function fCR [θC ] is continuous and bijective if the parameter space ΘC



















σ2Z < 0 and σ20|Z −σ21|Z < 0.
Proof. The function fM maps ΘC to ΘM in a continuous and bijective way. As conse-
quence, the function also maps the corresponding subsets Θ?C to Θ?M in a continuous and
bijective way. The function fMR maps the restricted parameter space Θ?M to ΘR in a con-
tinuous and bijective way. Since the composition of continuous and bijective functions
leads again to continuous bijective functions (see for example Arens et al. [2012, p. 33]),
the composition of the continuous and bijective functions fMR ◦fM : Θ?C →ΘR leads to the
continuous and bijective function fCR whose inverse is denoted by gCR : ΘR→Θ?C .
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The parameters θC can be obtained by solving fCR [θC ] for θC leading to the function gCR .
For the sake of completeness, the values of gCR at θC are given in the following by gCR [θR]:
µZ = λ+κ(µ1 +µ0),
σ2Z = κ2(σ21 +σ20 + 2ρ10σ1σ0) +σ2η,





κ2(σ21 +σ20 + 2ρ10σ1σ0) +σ2η
,


























κ2(σ21 +σ20 + 2ρ10σ1σ0) +σ2η
)
.
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The asymptotic variance of σ̂21 can be estimated by
Var[σ̂21] = 2
(










The asymptotic variance of σ̂20 can be estimated by
Var[σ̂20] = 2
(
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The asymptotic variance of ρ̂10 can be estimated by
Var[ρ̂10] =
1










σ̂41|Z(σ̂20|Z + β̂20 σ̂2Z)2
n
+
σ̂40|Z(σ̂21|Z + β̂21 σ̂2Z)2
m
+
















1|Z(β̂0− β̂1) + β̂31 σ̂20|Z
)











0|Z(β̂0− β̂1)− β̂30 σ̂21|Z
)































































+ α1 +α0 + (β̂1 + β̂0)µ̂Z(
























σ̂20|Z − σ̂21|Z + (β̂0− β̂1)2σ̂2Z
)(
2β̂1µ̂Z(σ̂20|Z − σ̂21|Z) +
(









σ̂21|Z − σ̂20|Z + (β̂0− β̂1)2σ̂2Z
)(
2β̂0µ̂Z(σ̂21|Z − σ̂20|Z) +
×
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2β̂0µ̂Z(σ̂20|Z − σ̂21|Z) +
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2β̂1µ̂Z(σ̂20|Z − σ̂21|Z) +
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The asymptotic variance for σ̂2η can be estimated by
Var[σ̂2η] =
2σ̂4Z(
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